Publication: Dislipidemide angiotensin çevirici enzim insersiyon/ delesyon polimorfizminin etkilerinin incelenmesi
Abstract
Metabolik hastalıkların patogenezinde renin-angiotensin sistemi (RAS) önemli rol oynar. Angiotensin-çevirici enzim (ACE) geni polimorfizmleri lipoprotein metabolizmasını düzenler. Araştırmamızın amaçlarından biri ACE geni ID polimorfizminin etiyolojik risk faktörü olarak dislipidemili ve dislipidemili olmayan kontrol bireylerdeki genotip sıklıklarının saptanmasıdır. ACE geni II, ID ve DD genotiplerinin demografik (boy, kilo), şişmanlık (beden kütle indeksi (BKİ), vücut yağı (VY), serum lipidleri), hipertansiyon (sistolik/ diastolik kan basıncı (SKB/ DKB)) ve açlık kan şekeri üzerindeki etkilerinin belirlenmesi çalışmanın diğer amaçlarındandır. Çalışmaya dislipidemi tanısı konmuş 97 dislipidemili ve 70 dislipidemili olmayan sağlıklı birey dahil edilmiştir. ACE geni ID polimorfizmi allel spesifik PCR yöntemi ile saptandı. ACE geni ID polimorfizmi genotip sıklıkları dislipidemililerde II, ID ve DD genotipleri için sırasıyla %14.4, %52.6, %33.0 ve normolipidemik grupta ise %15.7, %61.4, %22.9 olarak tespit edilmiştir. Dislipidemili grupta ACE geni II genotipine sahip bireylerde açlık kan şekeri düzeyleri diğer genotiplere kıyasla daha yüksek, ID genotipli bireylerde ise yağsız vücut kütlesi (YVK) diğer genotiplere kıyasla daha düşük olarak tespit edilmiştir. Dislipidemik ve normolipidemik çalışma gruplarında ACE ID genotip sıklıklarının benzer olduğu ve ACE geni ID polimorfizminin dislipidemili kişilerde plazma lipid-lipoprotein düzeylerine etkisinin olmadığı belirlenmiştir.
ANGIOTENSIN-CONVERTING ENZYME GENE INSERTION/ DELETION POLYMORPHISM IN DYSLIPIDEMIA The renin–angiotensin system (RAS) plays an important role in the pathogenesis of metabolic diseases. Polymorphisms in the angiotensin-converting enzyme (ACE) gene modulates lipoprotein metabolism. One of the aims of this study was to determine the ACE gene ID polymorphism genotype frequencies in dyslipidemic and normolipidemic control individuals as an etiological risk factor. Other aim of the study was to evaluate the effects of ACE gene II, ID and DD genotypes on demographic (height, weight), obesity (body mass index (BMI), body fat (BF), serum lipids), hypertension (systolic/ diastolic blood pressure (SBP/ DBP) and fasting plasma glucose). 97 dyslipidemic and 70 normo-lipidemic healthy individuals were included to the study. ACE ID polymorphism was determined by allele specific PCR. The II, ID and DD genotype frequencies were as 14.4%, 52.6% and 33.0% for the dyslipidemic subjects and 15.7%, 61.4% and 22.9% for the normolipidemic subjects, respectively. In dyslipidemics, glucose levels were significantly higher in II subjects when compared to ID and DD individuals and free fat mass was lower in ID subjects when compared to II and DD individuals. The allelic frequencies of ACE II, ID and DD were similar in dyslipidemic and normolipidemic subjects and ACE ID polymorphism was not found to be affective on plasma lipid-lipoprotein levels.
ANGIOTENSIN-CONVERTING ENZYME GENE INSERTION/ DELETION POLYMORPHISM IN DYSLIPIDEMIA The renin–angiotensin system (RAS) plays an important role in the pathogenesis of metabolic diseases. Polymorphisms in the angiotensin-converting enzyme (ACE) gene modulates lipoprotein metabolism. One of the aims of this study was to determine the ACE gene ID polymorphism genotype frequencies in dyslipidemic and normolipidemic control individuals as an etiological risk factor. Other aim of the study was to evaluate the effects of ACE gene II, ID and DD genotypes on demographic (height, weight), obesity (body mass index (BMI), body fat (BF), serum lipids), hypertension (systolic/ diastolic blood pressure (SBP/ DBP) and fasting plasma glucose). 97 dyslipidemic and 70 normo-lipidemic healthy individuals were included to the study. ACE ID polymorphism was determined by allele specific PCR. The II, ID and DD genotype frequencies were as 14.4%, 52.6% and 33.0% for the dyslipidemic subjects and 15.7%, 61.4% and 22.9% for the normolipidemic subjects, respectively. In dyslipidemics, glucose levels were significantly higher in II subjects when compared to ID and DD individuals and free fat mass was lower in ID subjects when compared to II and DD individuals. The allelic frequencies of ACE II, ID and DD were similar in dyslipidemic and normolipidemic subjects and ACE ID polymorphism was not found to be affective on plasma lipid-lipoprotein levels.